Propensity-matched study of liposomal doxorubicin vs. doxorubicin in first-line DLBCL treatment: efficacy and safety

Objective: Given the increasing use of pegylated liposomal doxorubicin (PLD) in diffuse large B-cell lymphoma (DLBCL) treatment due to its advantages in reducing adverse reactions, and the uncertainty surrounding its effective dose and corresponding efficacy in DLBCL, this study aims to compare it with the standard dose of conventional doxorubicin (DOX) in first-line DLBCL treatment. Methods: = 323]. Endpoints included progression-free survival (PFS), overall survival (OS), and toxicity. Results: < 0.001), with similar cardiac/pneumonia events. Elderly patients (≥60 years) mirrored overall efficacy/safety trends. Conclusion: ] offers a safer and potentially more effective alternative to standard DOX, while low-dose PLD maintains equivalent efficacy. These findings support optimized PLD dosing strategies in DLBCL therapy to enhance safety without compromising outcomes.